Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation

Liver Transplantation

Volumn 13, Issue 3, 2007, Pages 451-458

  Yi, Nam Joon ^a   Suh, Kyung Suk ^a   Cho, Jai Young ^a   Kwon, Choon Hyuck ^b   Lee, Kwang Woong ^b   Joh, Jae Woh ^b   Lee, Suk Koo ^b   Kim, Soo Il ^c   Lee, Kuhn Uk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; FLUOROURACIL; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DNA DETERMINATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION RISK; KOREA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PATIENT MONITORING; PATIENT SAFETY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VIRUS REPLICATION;

ADRENAL CORTEX HORMONES; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33947411477     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21043     Document Type: Article

References (29)

1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
2. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86-95.
3. Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 2005; 17:746-758
4. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-S85.
5. Marzano A. Gaia S, Ghisetti V, Carenzl S. Premoll A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005;11:402-409
6. Dementris AJ. Batts KP, Dhillon AP, Ferrell L, Fung J. Geller SA, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997:25:658-663.
7. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation Liver Transpl 2002:8:S67-S73.
8. Terault N. Roche, B. Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005;11: 716-732.
9. Kim WR, Poterucha JJ, Kremers WK. Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States Liver Transpl 2004;10:968-974.
10. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogue after liver transplantation for HBV infection. J Hepatol 2003;39:466-474.
11. Schreibman IR. Schiff ER. Prevention and treatment of recurrent Heaptitis B after liver transplantation: the current role nucleoside and nucleotide analogues. Ann Clin Microbial Antumicrob 2006;5:1-8.
12. Multimer D. Hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-1041.
13. Villeneuve JP. Condreay LD. Willems B, Pommier-Layrargues G, Fenyves D, Bilodeau M. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
14. Yao FY, Terault NA. Freise C, Maslow L. Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34;411-416
15. Fontana R, Keeffe E, Carey W. Fried M, Reddy R, Kowdley KW, et al. Effect of lamivudine, treatment on survival of 309 North American pattents meaning liver transplantation for chronic hepatitis B Liver Transpl 2002;8:433-439.
16. Lee HW, Suh KS, Yi NJ. Yang SH, Cho EH, Cho JY, et al. Preoperative lamivudine therapy in HBV DNA positive, recipients: is it necessary? Hepatogastroenterology. In press.
17. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002;8:S82-S87.
18. de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003;75: S49-S53.
19. Chang SH, Suh KS, Yi NJ, Choi SH. Lee HJ, Seo JK et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003;37:1329-1334.
20. Kwon CH, Suh KS, Yi NJ, Chang SH, Cho YB. Cho JY, et al. Long term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Ttansplant 2006;10: 479-286.
21. Sung HS, Oh HB. Hwang BK, Sohn MJ. Necessity of anti-HBc and anti-HBs sereening in Korean blood donation program: study using LG anti-HBc, and WL anti-HBs, ELISA kit and HBV nulceic, acid amplification test. Korean J Blood Transfus 2001;12:1-10.
22. Joo M, Bang SJ, Song BC, Youn KH. Jwo YH, Yang S, et al. Hepatitis B viral markers of Korean adults in the late 1990s: survey data of 70,347 health screenees Korean J Gastoenterol 1999;33:642-652.
23. Hwang S, Moon DB, Lee SG, Park KM, Kim KH, Ahn CS, et al. Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantaion. Transplantation 2003;75:S45-S48.
24. Minamiguchi S. Sakurai T. Fujita S. Okuno T, Haga H, Mino M, et al. Living related liver transplantation, histopathologic analysis of graft dysfunction in 304 patients. Hum Pathol 1999:30:1479-1487.
25. Nakagawa M, Simizu Y, Suemura M. Sato B. Successful long-term control with lamivudine against reactivated hepatitis B Infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases., Ann J Hematol 2002;70:60-63.
26. Stroffolini T, Andriani A. Bibas, M. Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin, lymphoma. Ann Hematol 2002;81:48-49.
27. Dai MS, Lu JJ, Chen YC, Perng CL, Chao TY. Reactivation of precore mutant hepatitis, B virus in chemotherapy-treated patients. Cancer 2001;92:2927-2932
28. Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 2001;15:599-603.
29. Yang HI, Lu SN, Liaw YF, You SL, San CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med 2002;347:168-174.